种间重组对肺炎链球菌氟喹诺酮耐药性的影响极小。
Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.
作者信息
Bast D J, de Azavedo J C, Tam T Y, Kilburn L, Duncan C, Mandell L A, Davidson R J, Low D E
机构信息
Department of Microbiology, Toronto Medical Laboratories and Mount Sinai Hospital, Toronto, Canada.
出版信息
Antimicrob Agents Chemother. 2001 Sep;45(9):2631-4. doi: 10.1128/AAC.45.9.2631-2634.2001.
Abstract
Analysis of 71 ciprofloxacin-resistant (MIC > or = 4 microg/ml) Streptococcus pneumoniae clinical isolates revealed only 1 for which the quinolone resistance-determining regions of the parC, parE, and gyrB genes were genetically related to those of viridans group streptococci. Our findings support the occurrence of interspecies recombination of type II topoisomerase genes; however, its contribution to the emergence of quinolone resistance among pneumococci appears to have been minimal.
摘要
对71株耐环丙沙星（最低抑菌浓度≥4微克/毫升）的肺炎链球菌临床分离株进行分析发现，只有1株分离株的parC、parE和gyrB基因的喹诺酮耐药决定区与草绿色链球菌的基因存在遗传关系。我们的研究结果支持II型拓扑异构酶基因种间重组的发生；然而，其对肺炎链球菌中喹诺酮耐药性出现的作用似乎很小。
相似文献
1
Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2001 Sep;45(9):2631-4. doi: 10.1128/AAC.45.9.2631-2634.2001.
2
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.
3
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329.
4
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810.
5
Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci.
Antimicrob Agents Chemother. 1999 Oct;43(10):2520-3. doi: 10.1128/AAC.43.10.2520.
6
Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:95-9. doi: 10.1093/jac/45.suppl_3.95.
7
Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2000 Apr;44(4):840-7. doi: 10.1128/AAC.44.4.840-847.2000.
8
In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.
J Infect Dis. 1999 Aug;180(2):555-8. doi: 10.1086/314888.
9
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
Antimicrob Agents Chemother. 2000 Nov;44(11):3049-54. doi: 10.1128/AAC.44.11.3049-3054.2000.
10
New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.
Antimicrob Agents Chemother. 2001 Mar;45(3):952-5. doi: 10.1128/AAC.45.3.952-955.2001.
引用本文的文献
1
serotypes that frequently colonise the human nasopharynx are common recipients of penicillin-binding protein gene fragments from .
Microb Genom. 2021 Sep;7(9). doi: 10.1099/mgen.0.000622.
2
Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.
Clin Microbiol Rev. 2016 Jul;29(3):525-52. doi: 10.1128/CMR.00058-15.
3
Mechanisms and impact of genetic recombination in the evolution of Streptococcus pneumoniae.
Comput Struct Biotechnol J. 2015 Apr 8;13:241-7. doi: 10.1016/j.csbj.2015.03.007. eCollection 2015.
4
Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.
Infection. 2012 Jun;40(3):239-62. doi: 10.1007/s15010-012-0257-2. Epub 2012 Mar 30.
5
Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.
Emerg Infect Dis. 2009 Jun;15(6):905-11. doi: 10.3201/eid1506.080684.
6
Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
Antimicrob Agents Chemother. 2008 Mar;52(3):822-30. doi: 10.1128/AAC.00731-07. Epub 2007 Dec 26.
7
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Antimicrob Agents Chemother. 2007 Jan;51(1):198-207. doi: 10.1128/AAC.00609-06. Epub 2006 Nov 6.
8
Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States.
Antimicrob Agents Chemother. 2005 Feb;49(2):779-80. doi: 10.1128/AAC.49.2.779-780.2005.
9
Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.
Emerg Infect Dis. 2004 Oct;10(10):1751-9. doi: 10.3201/eid1010.040382.
10
Genetic characterization of optochin-susceptible viridans group streptococci.
Antimicrob Agents Chemother. 2003 Oct;47(10):3187-94. doi: 10.1128/AAC.47.10.3187-3194.2003.
本文引用的文献
1
Quinolone Resistance: Older Concepts and Newer Developments.
Curr Infect Dis Rep. 2001 Feb;3(1):20-28. doi: 10.1007/s11908-001-0055-y.
2
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
Antimicrob Agents Chemother. 2000 Nov;44(11):3049-54. doi: 10.1128/AAC.44.11.3049-3054.2000.
3
In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2000 Oct;44(10):2740-6. doi: 10.1128/AAC.44.10.2740-2746.2000.
4
Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.
Antimicrob Agents Chemother. 2000 Aug;44(8):2197-200. doi: 10.1128/AAC.44.8.2197-2200.2000.
5
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
J Antimicrob Chemother. 2000 May;45(5):583-90. doi: 10.1093/jac/45.5.583.
6
Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2000 Apr;44(4):840-7. doi: 10.1128/AAC.44.4.840-847.2000.
7
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
Antimicrob Agents Chemother. 2000 Feb;44(2):462-6. doi: 10.1128/AAC.44.2.462-466.2000.
8
Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci.
Antimicrob Agents Chemother. 1999 Oct;43(10):2520-3. doi: 10.1128/AAC.43.10.2520.
9
In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.
Antimicrob Agents Chemother. 1999 Sep;43(9):2299-301. doi: 10.1128/AAC.43.9.2299.
10
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.
N Engl J Med. 1999 Jul 22;341(4):233-9. doi: 10.1056/NEJM199907223410403.
Zotero 插件